Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., announced new findings that show MHC-II protein expression is a more reliable predictor of response to pembrolizumab (Keytruda®) than the ...
News organizations may use or redistribute this image, with proper attribution, as part of news coverage of this paper only.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback